The short answer
Reta is informal shorthand for retatrutide. The full name follows WHO International Nonproprietary Name conventions: the -tide suffix denotes a peptide, and the preceding stem identifies its pharmacological class, -glutide marks a GLP-1 analogue, while -trutide marks the multi-receptor incretin agonists that retatrutide and tirzepatide belong to.
Key facts
- Reta
- Informal shorthand
- Full INN
- Retatrutide
- Development code
- LY3437943
- -tide suffix
- Denotes a peptide
- -glutide stem
- GLP-1 analogues
- -trutide stem
- Multi-receptor incretin agonists
How INN names are built
The WHO assigns International Nonproprietary Names using standardised stems that encode pharmacology. The suffix -tide marks a peptide. Within that, -glutide identifies GLP-1 analogues, which is why semaglutide, liraglutide and dulaglutide share it. Retatrutide and tirzepatide carry -trutide, marking the multi-receptor incretin agonists.
Why the naming system is useful
An unfamiliar drug name in a paper still tells you something. Anything ending -glutide is a GLP-1 analogue peptide. Anything ending -tide is a peptide at all. The stems are deliberately informative, which makes the system worth knowing rather than merely tolerating.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
INN versus development code
LY3437943 is Lilly's internal designation and appears in trial registrations and the discovery literature. Retatrutide is the INN, assigned as the compound progressed. Both refer to the same molecule, and searching both surfaces different records. The code finds earlier work, the INN finds later.
What an INN does not signify
Approval. An INN is assigned so a compound has one unambiguous generic name; it says nothing about regulatory status. DSIP holds an INN, emideltide, and is approved nowhere. Retatrutide holds one and is likewise approved nowhere.
Why the shorthand exists
Retatrutide is a mouthful, and abbreviated forms circulate in informal discussion. Reta carries no technical meaning and appears in no scientific literature. Searching for it finds forum and commercial content rather than research, in the same way TB-500 does.
Frequently asked questions
What does the -tide suffix mean?
That the compound is a peptide. Within that, -glutide marks GLP-1 analogues and -trutide marks multi-receptor incretin agonists.
Is reta used in scientific literature?
No. It is informal shorthand. Papers use retatrutide or the development code LY3437943.
Does having an INN mean it is approved?
No. An INN is a naming decision. DSIP holds one and is approved nowhere; so is retatrutide.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedCoskun T et al. Cell Metab 2022 (PMID 35985340)pubmed.ncbi.nlm.nih.gov
- WHOWHO: International Nonproprietary Nameswho.int
- PubMedJastreboff AM et al. NEJM 2023 (PMID 37366315)pubmed.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov · TRIUMPH-1 (NCT05929066). Retatrutide Phase 3 obesity trialclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-2 (NCT05929079). Retatrutide in type 2 diabetesclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-3 (NCT05882045). Retatrutide + established CVDclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-4 (NCT05931367). Retatrutide once weeklyclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-5 (NCT06662383). Retatrutide vs tirzepatideclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-6 (NCT06859268). Maintenance of weight reductionclinicaltrials.gov
- PubMedRosenstock J et al., Retatrutide for people with type 2 diabetes. Lancet 2023 (PMID 37385280)pubmed.ncbi.nlm.nih.gov
- DrugBankDrugBank · Retatrutide (DB18435)go.drugbank.com
- GuidelineGoogle: Creating helpful, reliable, people-first contentdevelopers.google.com
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More Retatrutide Research articles
- What "Reta" on a Label Actually Tells YouAn informal term for material sold as retatrutide for laboratory research. What the name does and does not tell you about the contents.
- Retatrutide vs Mounjaro, Ozempic and WegovyMounjaro is tirzepatide, Ozempic is semaglutide, and retatrutide is neither. One, two and three receptors - and why the headline figures rarely compare.
- Is Retatrutide FDA Approved? Regulatory Status ExplainedRetatrutide is not FDA approved. It is an investigational peptide in the Phase 3 TRIUMPH programme. Current EMA, MHRA and FDA regulatory status explained.
- Retatrutide Molecular Structure and PropertiesA lipidated 39-mer supplied as a white lyophilised powder. What the structure implies for solubility, handling and analysis.
- What Is a Triple Agonist?One molecule activating three receptors. Why that differs from combination therapy, and what it buys and costs relative to giving three drugs.